Literature DB >> 16939

Studies on the pathogenesis of an immune defect in multiple myeloma.

T Paglieroni, M R MacKenzie.   

Abstract

The reduced capacity of patients with multiple myeloma to respond to antigen challenge is well recognized. Response to antigen involves antigen recognition, cell proliferation, and synthesis and secretion of antibody. This study examines this sequence of events in peripheral blood lymphocytes from untreated and treated patients with myeloma, from individuals with benign monoclonal gammopathy, and from normal healthy donors. Antigen-binding capacity was assessed by testing the ability of lymphocytes to bind radio-labeled pneumococcal polysaccharide, tetanus toxoid, or diptheria toxin. The in vitro proliferative response to these antigens as well as to pokeweed mitogen and streptokinase-streptodornase was evaluated. The secretion of immunoglobulin in response to pneumococcal polysaccharide, tetanus toxoid, and pokeweed mitogen by 2-4 x 10(6) lymphocytes in 7-day cultures was determined. The effects of coculture of myeloma peripheral blood lymphocytes and normal peripheral blood lymphocytes on immunoglobulin production and mixed leukocyte reactions were explored. All myeloma patients had normal numbers (3-8/5,000 cells) of antigen-binding cells. However, most showed a diminished antigen-induced blast transformation as measured by uptake of [(125)I]5-iodo-2'-deoxyuridine in culture. Immunoglobulin production in response to specific antigen in myeloma lymphocytes was 30-80% less than in normal lymphocytes. Immunoglobulin synthesis and mixed leukocyte responses by normal peripheral blood lymphocytes could be suppressed by myeloma lymphocytes. Multiple suppressor populations were present. Thus, the immune defect in myeloma is beyond the antigen recognition step and involves both the proliferation of antigen-sensitive cells and immunoglobulin production. Further suppressive effects are imposed on normal cells, implying defects in immunoregulation in this disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 16939      PMCID: PMC372325          DOI: 10.1172/JCI108736

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Letter: Suppressor cells and human malignant disease.

Authors:  J G Sinkovics
Journal:  Br Med J       Date:  1976-05-01

2.  IMMUNOLOGICAL DEFICIENCY DISORDERS ASSOCIATED WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA.

Authors:  L CONE; J W UHR
Journal:  J Clin Invest       Date:  1964-12       Impact factor: 14.808

3.  Phagocytes and C4 in paraproteinaemia.

Authors:  L E Spitler; P Spath; L Petz; N Cooper; H H Fudenberg
Journal:  Br J Haematol       Date:  1975-02       Impact factor: 6.998

4.  Suppression of B-cell differentiation by leukocytes from hypogammaglobulinemic patients.

Authors:  F P Siegal; M Siegal; R A Good
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

5.  Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells.

Authors:  S Broder; R Humphrey; M Durm; M Blackman; B Meade; C Goldman; W Strober; T Waldmann
Journal:  N Engl J Med       Date:  1975-10-30       Impact factor: 91.245

6.  Hodgkin's disease. An immunodepleting and immunosuppressive disorder.

Authors:  J J Twomey; A H Laughter; S Farrow; C C Douglass
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

7.  Suppressor cells in tumor-bearing mice capable of nonspecific blocking of in vitro immunization against transplant antigens.

Authors:  A E Eggers; J R Wunderlich
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

8.  Identification of cells with monocyte markers in panhypogammaglobulinaemia.

Authors:  A R Hayward; M F Greaves
Journal:  Scand J Immunol       Date:  1975-09       Impact factor: 3.487

9.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

10.  Immunoglobulins on the surface of lymphocytes. I. Distribution and quantitation.

Authors:  E Rabellino; S Colon; H M Grey; E R Unanue
Journal:  J Exp Med       Date:  1971-01-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  The mechanism of the immunologic deficiency in myeloma of man and mouse.

Authors:  P Heller
Journal:  Blut       Date:  1978-08-15

3.  Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization.

Authors:  R H Stevens; A Saxon
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

Review 4.  Mechanisms in secondary hypogammaglobulinaemia.

Authors:  P G Riches; J R Hobbs
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

5.  Immunosuppression in plasmacytoma: induction of suppressor cells.

Authors:  Y Chen; L T Hwang; P Heller
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

6.  T-cell imbalances in patients with multiple myeloma: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; H J Hansen; J R Redman; S Berenson; B J Lee; B D Clarkson
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

7.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

8.  The mode of action of splenic suppressor cells in murine plasmacytoma.

Authors:  Y Chen; P Heller
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

9.  Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease.

Authors:  F Lauria; R Foa; M Cavo; M Gobbi; D Raspadori; M C Giubellino; P L Tazzari; S Tura
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

10.  The effect of ranitidine on cellular immunity in patients with multiple myeloma.

Authors:  H J Nielsen; H Nielsen; F Moesgaard; N Tvede; K Klarlund; B Mansa; A Drivsholm
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.